| Setting | No. of patients | Country in which study was conducted | Reported prevalence of primary aldosteronism, % |
|---|---|---|---|
| Unselected/primary care hypertension | |||
| Loh K et al. (19) | 350 | Singapore | 5 |
| Fogari et al. (17) | 3000 | Italy | 5.9 |
| Omura et al. (20) | 1020 | Japan | 6.0 |
| Referred to specialty hypertension clinic/resistant hypertension | |||
| Rossi et al. (6) | 1125 | Italy | 11.2 |
| Lim et al. (22) | 465 | UK | 9.2 |
| Abdelhamid et al. (23) | 3900 | Germany | 6.6 |
| Stowasser et al. (24) | 300 | Australia | 18 |
| Yin et al. (25) | 313 | China | 12.5 |
| Milliez et al. (26) | 5438 | France | 2.3† |
| Matrozova et al. (27) | 376 | Bulgaria | 6.9 |
| Strauch et al. (15) | 402 | Czech Republic | 19 |
* Minimum of 300 participants.
↵† Extremely restrictive definition of primary aldosteronism.